Table 2.
3DCRT (151 observations)a | IMRT (240 observations)a | PBT (144 observations)a | |||||||
---|---|---|---|---|---|---|---|---|---|
Est | SE | P | Est | SE | P | Est | SE | P | |
During CXRT (weeks 1–7) | |||||||||
Pain | 0.43 | 0.09 | < 0.001 | 0.44 | 0.08 | < 0.001 | 0.20 | 0.08 | 0.024 |
Sore throat | 0.65 | 0.10 | < 0.001 | 0.50 | 0.08 | < 0.001 | 0.10b | 0.06 | 0.097 |
Fatigue | 0.22 | 0.08 | 0.019 | 0.41 | 0.07 | < 0.001 | 0.16 | 0.10 | 0.132 |
Drowsiness | 0.30 | 0.11 | 0.016 | 0.32 | 0.06 | < 0.001 | 0.22 | 0.10 | 0.050 |
Lack of appetite | 0.48 | 0.12 | < 0.001 | 0.36 | 0.08 | < 0.001 | 0.16 | 0.11 | 0.151 |
Disturbed sleep | 0.15 | 0.12 | 0.249 | 0.06 | 0.08 | 0.409 | 0.02 | 0.11 | 0.826 |
Post-CXRT (weeks 7–12) | |||||||||
Pain | –0.14 | 0.14 | 0.308 | –0.40 | 0.13 | 0.005 | –0.10 | 0.10 | 0.341 |
Sore throat | –0.54 | 0.15 | 0.001 | –0.37 | 0.12 | 0.004 | –0.06 | 0.07 | 0.409 |
Fatigue | –0.14 | 0.08 | 0.093 | –0.44 | 0.11 | < 0.001 | 0.19 | 0.12 | 0.117 |
Drowsiness | –0.11 | 0.11 | 0.352 | –0.31 | 0.10 | 0.003 | –0.06 | 0.11 | 0.599 |
Lack of appetite | –0.48 | 0.14 | 0.002 | –0.28 | 0.13 | 0.037 | –0.13 | 0.13 | 0.317 |
Disturbed sleep | –0.30 | 0.13 | 0.030 | –0.04 | 0.12 | 0.728 | –0.03 | 0.12 | 0.796 |
3DCRT = three-dimensional conformal radiation therapy; CXRT = concurrent chemoradiation therapy; Est = estimate of the effect of independent variables (or factors) on symptoms; IMRT = intensity-modulated radiotherapy; PBT = proton-beam therapy; SE = standard error.
Age, sex, race, cancer stage, Eastern Cooperative Oncology Group performance status, body mass index, total radiation dose, previous chemotherapy, and previous surgery were included as covariates in all models. Estimate value represents the average weekly change in symptom score on the MDASI’s 0–10 scale, with a positive score indicating increased severity.
This item was worded as “mouth or throat sores” in the PBT group.